This company has been marked as potentially delisted and may not be actively trading. Rapt Therapeutics (RAPT) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock Get the Latest News and Ratings for RAPT and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Rapt Therapeutics and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RAPT Analyst Ratings Over TimeTypeCurrent Forecast5/22/25 to 5/22/261 Month Ago4/22/25 to 4/22/263 Months Ago2/21/25 to 2/21/261 Year Ago5/22/24 to 5/22/25Strong Buy1 Strong Buy rating(s)1 Strong Buy rating(s)1 Strong Buy rating(s)1 Strong Buy rating(s)Buy1 Buy rating(s)1 Buy rating(s)1 Buy rating(s)1 Buy rating(s)Hold10 Hold rating(s)10 Hold rating(s)10 Hold rating(s)3 Hold rating(s)Sell1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)Consensus Price Target$48.44$48.44$48.44$24.00Forecasted Upside-16.50% Downside-16.50% Downside-16.36% Downside249.61% UpsideConsensus RatingHoldHoldHoldHold RAPT Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History RAPT Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Rapt Therapeutics Stock vs. The CompetitionTypeRapt TherapeuticsMedical CompaniesBroader MarketConsensus Rating Score 2.15 2.30 2.52Consensus RatingHoldHoldModerate BuyPredicted Upside-16.50% Downside1,716.74% Upside15.96% UpsideNews Sentiment RatingNeutral NewsSee Recent RAPT NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails1/22/2026 Weiss RatingsNot Rated Reiterated RatingSell (D-)1/21/2026 Barclays3 of 5 starsEtzer DaroutNot RatedDowngradeOverweight ➝ Equal Weight$58.00+0.69%1/20/2026 TD Cowen3 of 5 starsYaron WerberNot RatedDowngradeBuy ➝ Hold1/20/2026 GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingYatin SunejaSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeBuy ➝ Neutral1/20/2026 Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating DowngradeOverweight ➝ Neutral$58.00+0.84%1/20/2026 Clear StrSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating DowngradeStrong-Buy ➝ Hold1/20/2026 Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating DowngradeOutperform ➝ Hold1/20/2026 Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingYanan ZhuSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$58.00+0.79%1/20/2026 HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingEmily BodnarSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeBuy ➝ Neutral$58.00+0.84%11/12/2025 JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAnupam RamaSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetOverweight$55.00 ➝ $57.00+92.70% Get the Latest News and Ratings for RAPT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Rapt Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 9/26/2025 Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingThomas SmithSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$16.00 ➝ $37.00+51.33%8/22/2025 Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating DowngradeStrong-Buy ➝ Hold8/12/2025 UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingEliana MerleSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingSet TargetNeutral$8.00 ➝ $9.00-5.46%11/13/2024 Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Reiterated RatingBuy ➝ Hold$56.00 ➝ $16.00+14.94%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 02:45 PM ET. RAPT Forecast - Frequently Asked Questions What is Rapt Therapeutics' forecast for 2026? According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Rapt Therapeutics is $48.44, with a high forecast of $70.00 and a low forecast of $9.00. Should I buy or sell Rapt Therapeutics stock right now? 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rapt Therapeutics in the last year. There is currently 1 sell rating, 10 hold ratings, 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" RAPT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RAPT, but not buy additional shares or sell existing shares. Does Rapt Therapeutics's stock price have much downside? According to analysts, Rapt Therapeutics's stock has a predicted downside of -16.50% based on their 12-month stock forecasts. Do Wall Street analysts like Rapt Therapeutics more than its competitors? Analysts like Rapt Therapeutics less than other "medical" companies. The consensus rating score for Rapt Therapeutics is 2.15 while the average consensus rating score for "medical" companies is 2.30. Learn more on how RAPT compares to other companies. Stock Forecasts and Research Tools Related Companies Protagonist Therapeutics Stock Forecast Belite Bio Stock Forecast CG Oncology Stock Forecast Terns Pharmaceuticals Stock Forecast PTC Therapeutics Stock Forecast Lantheus Stock Forecast Cogent Biosciences Stock Forecast Centessa Pharmaceuticals Stock Forecast Immunovant Stock Forecast Scholar Rock Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With Rapt Therapeutics RecommendationsWall Street ZenWeiss RatingsBarclaysHC WainwrightWells Fargo & CompanyTD CowenPiper SandlerLifesci CapitalGuggenheimClear StrJPMorgan Chase & Co.Leerink PartnersZacks ResearchUBS Group This page (NASDAQ:RAPT) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredMaybe the Greatest Strategy of the DecadeNate Bear, Lead Technical Tactician at Monument Traders Alliance, is going public with his highest-conviction ...Monument Traders Alliance | SponsoredTo Avoid 67 Million Blackouts, Trump Signs Emergency Backing of New Energy TechPresident Trump has used emergency executive powers to back a new energy technology described as 326 times mor...Altimetry | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredHidden on Tesla's filing: A $12 billion "super startup"Tesla's most recent SEC filing contains a single line showing $12 billion in revenue from a new venture Elon M...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapt Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapt Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
